MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC

MYC ecDNA促进PDAC的肿瘤内异质性和可塑性。

阅读:16
作者:Elena Fiorini #,Antonia Malinova #,Daniel Schreyer #,Davide Pasini,Michele Bevere,Giorgia Alessio,Diego Rosa,Sabrina D'Agosto,Luca Azzolin,Salvatore Milite,Silvia Andreani,Francesca Lupo,Lisa Veghini,Sonia Grimaldi,Serena Pedron,Monica Castellucci,Craig Nourse,Roberto Salvia,Giuseppe Malleo,Andrea Ruzzenente,Alfredo Guglielmi,Michele Milella,Rita T Lawlor,Claudio Luchini,Antonio Agostini,Carmine Carbone,Christian Pilarsky,Andrea Sottoriva,Aldo Scarpa,David A Tuveson,Peter Bailey,Vincenzo Corbo

Abstract

Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance1,2. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity3, thereby providing a substrate for somatic evolution. Nonetheless, the genetic mechanisms underlying phenotypic heterogeneity are still poorly understood. Here we show that extrachromosomal DNA (ecDNA) is a major source of high-level focal amplification in key oncogenes and a major contributor of MYC heterogeneity in pancreatic ductal adenocarcinoma (PDAC). We demonstrate that ecDNAs drive varying levels of MYC dosage, depending on their regulatory landscape, enabling cancer cells to rapidly and reversibly adapt to microenvironmental changes. In the absence of selective pressure, a high ecDNA copy number imposes a substantial fitness cost on PDAC cells. We also show that MYC dosage affects cell morphology and dependence of cancer cells on stromal niche factors. Our work provides a detailed analysis of ecDNAs in PDAC and describes a new genetic mechanism driving MYC heterogeneity in PDAC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。